RARE
NASD Ultragenyx Pharmaceutical, Inc.$15.45 ↑ +0.16 (+1.05%) Trading Up from the previous close of $15.29
- YTD change
- -32.83%
- vs 20-day SMA
- +6.13%
- vs 200-day SMA
- -34.84%
Price ranges
Price & Performance
-8.62 (-36.05%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 91.4% away from all-time highs of $179.65
- RARE is down 33% since the beginning of the year
- RARE is down 51% over the past 12 months
- RARE is up 7% over the past 1 month
- 18% of all RARE investors are betting against RARE
RARE reads very good: price sits above one of the two key moving averages, the 12-month move is -51.7%.
- Previous minute
- +$0.00
- Last hour
- +$0.35
- Last 5 days
- +4.75%
- vs 8-day SMA
- +3.47%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.